O	0	1	A
O	2	12	randomized
O	13	23	controlled
O	24	29	Phase
O	30	32	II
O	33	38	trial
O	39	41	of
B-intervention	42	53	vinorelbine
I-intervention	54	58	plus
I-intervention	59	71	capecitabine
O	72	78	versus
B-control	79	88	docetaxel
I-control	89	93	plus
I-control	94	106	capecitabine
O	107	109	in
O	110	123	anthracycline
O	123	124	-
O	124	134	pretreated
O	135	140	women
O	141	145	with
O	146	156	metastatic
O	157	163	breast
O	164	170	cancer
O	170	171	.

O	172	180	Previous
O	181	188	studies
O	189	193	have
O	194	199	shown
O	200	204	that
O	205	216	vinorelbine
O	216	217	/
O	217	229	capecitabine
O	230	231	(
O	231	233	NX
O	233	234	)
O	235	238	and
O	239	248	docetaxel
O	248	249	/
O	249	261	capecitabine
O	262	263	(
O	263	265	TX
O	265	266	)
O	267	279	chemotherapy
O	280	283	has
O	284	285	a
O	286	293	certain
O	294	300	effect
O	301	303	in
O	304	312	advanced
O	313	319	breast
O	320	326	cancer
O	326	327	.

O	328	335	However
O	335	336	,
O	337	342	there
O	343	346	are
O	347	350	few
O	351	359	clinical
O	360	367	studies
O	368	376	directly
O	377	386	comparing
O	387	389	TX
O	390	393	and
O	394	396	NX
O	397	404	regimen
O	405	417	chemotherapy
O	417	418	,
O	419	429	especially
O	430	432	in
O	433	441	patients
O	442	446	with
O	447	455	advanced
O	456	462	breast
O	463	469	cancer
O	470	480	previously
O	481	488	treated
O	489	493	with
O	494	507	anthracycline
O	508	511	and
O	512	518	taxane
O	518	519	.

O	520	523	The
O	524	531	purpose
O	532	534	of
O	535	539	this
O	540	545	Phase
O	546	548	II
O	549	554	study
O	555	558	was
O	559	561	to
O	562	569	compare
O	570	578	survival
O	579	582	and
O	583	587	side
O	588	595	effects
O	596	603	between
O	604	612	patients
O	613	617	with
O	618	631	anthracycline
O	631	632	-
O	633	636	and
O	637	643	taxane
O	643	644	-
O	644	653	resistant
O	654	662	advanced
O	663	669	breast
O	670	676	cancer
O	677	684	treated
O	685	689	with
O	690	692	NX
O	693	696	and
O	697	702	those
O	703	710	treated
O	711	715	with
O	716	718	TX
O	719	731	chemotherapy
O	731	732	.

O	733	737	From
O	738	746	February
O	747	751	2012
O	752	754	to
O	755	760	March
O	761	765	2014
O	765	766	,
O	767	768	a
O	769	774	total
O	775	781	number
O	782	784	of
B-total-participants	785	787	97
O	788	796	patients
O	797	801	were
O	802	810	randomly
O	811	819	assigned
O	820	822	to
O	823	825	NX
O	826	827	(
O	827	828	n
O	829	830	=
B-intervention-participants	831	833	55
O	833	834	)
O	835	837	or
O	838	840	TX
O	841	842	(
O	842	843	n
O	844	845	=
B-control-participants	846	848	42
O	848	849	)
O	849	850	.

O	851	859	Baseline
O	860	875	characteristics
O	876	880	were
O	881	891	relatively
O	892	896	well
O	896	897	-
O	897	905	balanced
O	906	908	in
O	909	912	the
O	913	916	two
O	917	926	treatment
O	927	931	arms
O	931	932	.

O	933	936	The
O	937	945	clinical
O	946	951	trial
O	952	964	registration
O	965	971	number
O	972	973	(
O	973	986	clincaltrials
O	986	987	.
O	988	991	gov
O	991	992	)
O	993	995	is
O	996	1007	NCT01635465
O	1007	1008	.

O	1009	1014	After
O	1015	1016	a
O	1017	1023	median
O	1024	1030	follow
O	1030	1031	-
O	1031	1033	up
O	1034	1036	of
O	1037	1039	46
O	1039	1040	.
O	1040	1041	0
O	1042	1048	months
O	1048	1049	,
O	1050	1055	there
O	1056	1059	was
O	1060	1062	no
O	1063	1074	significant
O	1075	1085	difference
O	1086	1093	between
O	1094	1097	the
O	1098	1100	NX
O	1101	1104	and
O	1105	1107	TX
O	1108	1112	arms
O	1113	1115	in
B-outcome	1116	1125	objective
I-outcome	1126	1134	response
I-outcome	1135	1139	rate
O	1140	1141	(
B-iv-bin-percent	1141	1143	17
I-iv-bin-percent	1143	1144	.
I-iv-bin-percent	1144	1145	9
I-iv-bin-percent	1145	1146	%
O	1147	1149	vs
O	1149	1150	.
B-cv-bin-percent	1151	1153	21
I-cv-bin-percent	1153	1154	.
I-cv-bin-percent	1154	1155	1
I-cv-bin-percent	1155	1156	%
O	1156	1157	;
O	1158	1159	P
O	1160	1161	=
O	1162	1163	0
O	1163	1164	.
O	1164	1167	686
O	1167	1168	)
O	1169	1172	and
B-outcome	1173	1184	progression
I-outcome	1184	1185	-
I-outcome	1185	1189	free
I-outcome	1190	1198	survival
O	1199	1200	(
B-iv-cont-median	1200	1201	6
I-iv-cont-median	1202	1208	months
O	1209	1211	vs
O	1211	1212	.
B-cv-cont-median	1213	1214	7
I-cv-cont-median	1215	1221	months
O	1221	1222	;
O	1223	1224	P
O	1225	1226	=
O	1227	1228	0
O	1228	1229	.
O	1229	1232	560
O	1232	1233	)
O	1233	1234	.

O	1235	1238	The
B-outcome	1239	1246	overall
I-outcome	1247	1255	survival
O	1256	1262	period
O	1263	1265	of
O	1266	1269	the
O	1270	1272	TX
O	1273	1276	arm
O	1277	1280	was
O	1281	1287	longer
O	1288	1292	than
O	1293	1297	that
O	1298	1300	of
O	1301	1304	the
O	1305	1307	NX
O	1308	1311	arm
O	1312	1313	(
B-iv-cont-median	1313	1315	32
I-iv-cont-median	1316	1322	months
O	1323	1325	vs
O	1325	1326	.
B-cv-cont-median	1327	1329	27
I-cv-cont-median	1330	1336	months
O	1336	1337	)
O	1338	1341	but
O	1342	1349	without
O	1350	1361	statistical
O	1362	1374	significance
O	1374	1375	.

O	1376	1380	Both
O	1381	1389	regimens
O	1390	1394	were
B-outcome	1395	1399	well
I-outcome	1399	1400	-
I-outcome	1400	1409	tolerated
O	1409	1410	.

O	1411	1414	The
O	1415	1419	main
O	1420	1430	toxicities
O	1431	1435	were
B-outcome	1436	1447	neutropenia
O	1447	1448	,
B-outcome	1449	1459	leukopenia
O	1459	1460	,
O	1461	1464	and
B-outcome	1465	1471	anemia
O	1471	1472	.

O	1473	1475	In
O	1476	1479	the
O	1480	1482	TX
O	1483	1486	arm
O	1486	1487	,
B-outcome	1488	1492	hand
I-outcome	1492	1493	-
I-outcome	1493	1497	foot
I-outcome	1498	1506	syndrome
O	1507	1515	occurred
O	1516	1520	more
O	1521	1531	frequently
O	1532	1536	than
O	1537	1539	in
O	1540	1543	the
O	1544	1546	NX
O	1547	1550	arm
O	1551	1552	(
O	1552	1553	P
O	1554	1555	<
O	1556	1557	0
O	1557	1558	.
O	1558	1560	01
O	1560	1561	)
O	1561	1562	,
O	1563	1566	but
O	1567	1578	frequencies
O	1579	1581	of
O	1582	1587	other
O	1588	1593	minor
B-outcome	1594	1601	adverse
I-outcome	1602	1609	effects
O	1610	1614	were
O	1615	1622	similar
O	1623	1630	between
O	1631	1634	the
O	1635	1638	two
O	1639	1643	arms
O	1643	1644	.

O	1645	1647	NX
O	1648	1651	and
O	1652	1654	TX
O	1655	1663	regimens
O	1664	1667	are
O	1668	1672	both
O	1673	1684	alternative
O	1685	1695	treatments
O	1696	1699	for
O	1700	1708	patients
O	1709	1713	with
O	1714	1727	anthracycline
O	1727	1728	-
O	1729	1732	and
O	1733	1739	taxane
O	1739	1740	-
O	1740	1749	resistant
O	1750	1758	advanced
O	1759	1765	breast
O	1766	1772	cancer
O	1772	1773	,
O	1774	1777	but
O	1778	1781	the
O	1782	1788	safety
O	1789	1796	profile
O	1797	1800	was
O	1801	1805	more
O	1806	1815	favorable
O	1816	1819	and
O	1820	1830	manageable
O	1831	1835	with
O	1836	1839	the
O	1840	1842	NX
O	1843	1850	regimen
O	1850	1851	.

O	1852	1866	ClinicalTrials
O	1866	1867	.
O	1868	1871	gov
O	1872	1883	NCT01635465
O	1883	1884	.

O	1885	1895	Registered
O	1896	1898	09
O	1899	1903	July
O	1904	1908	2012
O	1908	1909	.
